EverPoint Asset Management’s Achillion Pharmaceuticals ACHN Stock Holding History

EverPoint Asset Management’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,600,000	Closed	-$17.3M	–	588
2015 Q4	$17.3M	Sell	1,600,000 -900,000	-36%	-$8.18M	0.36%	82
2015 Q3	$17.3M	Buy	2,500,000 +650,000	+35%	+$5.3M	0.45%	51
2015 Q2	$16.4M	Buy	+1,850,000	New	+$17.5M	0.3%	98
2014 Q4	–	Sell	-250,000	Closed	-$2.5M	–	591
2014 Q3	$2.5M	Sell	250,000 -150,000	-38%	-$1.39M	0.06%	334
2014 Q2	$3.03M	Buy	+400,000	New	+$1.6M	0.06%	352

Other funds holding ACHN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EverPoint Asset Management's ACHN Position: Q1 2016 in Review

EverPoint Asset Management sold out of Achillion Pharmaceuticals (ACHN) in Q1 2016, closing a stake of 1,600,000 shares — an estimated $17.3M sold.

EverPoint Asset Management first reported a position in ACHN in Q2 2014 and held it in 5 quarters. The position peaked at $17.3M in Q3 2015. 153 funds tracked by Wall St. Rank hold ACHN as of Q1 2016.

EverPoint Asset Management reported no remaining Achillion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
EverPoint Asset Management sold 1,600,000 Achillion Pharmaceuticals shares in Q1 2016, an estimated $17.3M.
EverPoint Asset Management first reported a position in Achillion Pharmaceuticals in Q2 2014 and held it in 5 quarters.
EverPoint Asset Management's Achillion Pharmaceuticals position peaked at $17.3M in Q3 2015.
153 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2016.

Based on EverPoint Asset Management's 13F filing for Q1 2016, filed 16 May 2016.